Filters
Single-cell transcriptomics for the analysis of subclonal heterogeneity and clonal evolution of mantle cell lymphoma (GA23-05377S)
on subclonal heterogeneity and relevance of lymphoma cell lines and PDX models in direct lines and patient-derived xenografts (PDX) represent important tools in preclinical established lymphoma cell lines and PDXs...
Hematology
- 2023 - 2025 •
- 15 740 tis. Kč •
- 15 716 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2023 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Casein kinase 1 alpha (CK1a) inhibition as a novel therapeutic approach for AML (NW25-03-00225)
PDX model (patient-derived xenografts) in vivo. In addition, the project. Finally, we will create in vitro models mimicking the emergence of resistance to CK1......
Oncology
- 2025 - 2028 •
- 14 136 tis. Kč •
- 14 136 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2025 - 31. 12. 2028
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Humanized patient-derived murine xenografts for experimental therapy of hematologic malignancies and for the study of in vivo acquired drug-resistance (NV19-08-00144)
Republic. Patient-derived murine xenografts (PDXs) derived by injection of primary on sufficient numbers of biologically-relevant PDXs might in near future replace most of the proof-of-concept phase 2 studies. We plan to use the de...
Hematology
- 2019 - 2022 •
- 16 966 tis. Kč •
- 16 966 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2019 - 31. 12. 2022
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
DEVELOPMENT OF MODELS FOR THE STUDIES OF MICROENVIRONMENT AND THERAPEUTIC RESISTANCE IN B CELL MALIGNANCIES (NU23-08-00448)
and the generation of a novel patient-derived xenograft (PDX) model (AIM 2). We will also test to develop and characterize an in vitro co-culture model inducing stable and long-term% proliferating CLL cells in a 1-week co-...
Hematology
- 2023 - 2026 •
- 11 906 tis. Kč •
- 11 906 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2023 - 31. 12. 2026
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Upgrade of the Czech Centre for Phenogenomics developing towards translation research (EF16_013/0001789)
unit PDX models - New statistical methods, visualization techniques, and dynamic web interface for PDX and aging data. - Virtual tools, cloud computing on the aging process genes involved in this process) and oncology (pat...
EI - Biotechnologie a bionika
- 2017 - 2020 •
- 62 149 tis. Kč •
- 62 149 tis. Kč •
- MŠMT
Řešení projektu: 1. 5. 2017 - 31. 12. 2020
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo školství, mládeže a tělovýchovy
Discovery and development of novel tumor-suppressor-based reactivation cancer therapies (NW25-03-00073)
preclinical studies and validations in human tumor explant assays and in CDX and PDX mouse...
Oncology
- 2025 - 2028 •
- 19 501 tis. Kč •
- 18 255 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2025 - 31. 12. 2028
Uznané náklady
Podpora ze státního rozpočtu (94%)
Poskytovatel: Ministerstvo zdravotnictví
The impact of cytidine metabolic pathways on cytarabine therapy of hematological malignancies and new diagnostic tools for their analysis (NU22-08-00148)
Cytidine deaminase (CDA) and deoxycytidine monophosphate deaminase (DCTD), deoxycytidine kinase (dCK), 5'-nucleotidase and human equilibrative nucleoside transporter (hENT1) participate in the regulation of cellular nucleotide and nucleoside pools an...
Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])
- 2022 - 2025 •
- 10 318 tis. Kč •
- 10 318 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2022 - 31. 12. 2025
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Dual FLT3/CDK9 inhibition as a possible therapeutical approach for mixed lineage leukemia (GA19-09086S)
will be explored in MLL leukemia cell lines, in a genetically engineered mouse model of MLL-ENL-driven leukemia and in patient-derived xenograft (PDX) models.......
Oncology
- 2019 - 2023 •
- 9 576 tis. Kč •
- 9 576 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2019 - 31. 12. 2023
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Transplantation of islets generated in vitro from stem cells of adult pancreas (NR8031)
The aim of the project is to induce the proliferation of stem cells isolated from adult rat and human pancreases and to enable them to differentiate towards the phenotype of pancreatic cells. The cell quality will be tested by means of expression of ...
FJ - Chirurgie včetně transplantologie
- 2004 - 2006 •
- 3 225 tis. Kč •
- 3 026 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2004 - 1. 1. 2006
Uznané náklady
Podpora ze státního rozpočtu (94%)
Poskytovatel: Ministerstvo zdravotnictví
New prognostic and predictive markers in patients with mantle cell lymphoma at diagnosis and on treatment (NV17-28980A)
therapy of relapsed MCL, and 5. characterization of new PDX (patient derived xenograft) models and MCL cell lines derived from MCL patients after failure of targeted......
FD - Onkologie a hematologie
- 2017 - 2020 •
- 19 831 tis. Kč •
- 19 831 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2017 - 31. 12. 2020
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 out of 10 718